Vlado Perkovic is Dean and Scientia Professor of Medicine at UNSW Sydney. He is also a Professorial Fellow at The George Institute and a Staff Specialist in Nephrology at the Royal North Shore Hospital in Sydney.

Kidney Compass: New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026

The treatment landscape for IgA nephropathy (IgAN) continues to evolve at a rapid pace, and new data presented at the World Congress of Nephrology (WCN) in Yokohama, Japan, suggest a potential shift in how clinicians approach disease modification in high-risk patients. In this episode of 

, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Vlado Perkovic, MBBS, PhD, about newly presented 2-year eGFR slope data from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan.

Perkovic explained that the trial built on previously published findings in the 

 showing a 38% reduction in proteinuria at 9 months, but emphasized that the key question remained whether this would translate into long-term kidney protection. As he noted during the discussion, the study enrolled a particularly high-risk population, with median proteinuria around 1.7 g/g and rapid progression in the placebo arm—where eGFR declined by more than 6 mL/min/1.73 m² per year. Both hosts highlighted how this rate of decline reinforced the urgency for new therapies.

According to Perkovic, treatment with iptacopan slowed that decline to just over 3 mL/min/1.73 m² annually, representing an approximately 50% reduction compared with placebo and a treatment effect that exceeded initial expectations. Wadhwani and Neuen both pointed to this magnitude of benefit as especially compelling, particularly given that the trial was powered for a much smaller difference. Perkovic further noted that the key secondary composite endpoint, 30% eGFR decline or kidney failure, was reduced by 43%, which the hosts emphasized as evidence that the slope findings are likely to translate into meaningful clinical outcomes.

Safety was another focal point of the conversation. Perkovic noted that adverse events, serious adverse events, and discontinuations were comparable between groups, with no deaths reported. While he acknowledged a numerical increase in infections with iptacopan, he emphasized that all cases were manageable and resolved with treatment, and there was no concerning signal for severe or encapsulated infections.

The discussion then shifted to how iptacopan might fit into an increasingly complex treatment paradigm. Wadhwani raised the question of where complement inhibition would sit alongside existing therapies and evolving guideline recommendations, prompting Perkovic to stress that foundational treatments such as renin-angiotensin system inhibitors and SGLT2 inhibitors remain essential. However, he noted that patients receiving SGLT2 inhibitors in the trial still derived clear additional benefit, supporting the idea of combination therapy.

Neuen also highlighted the importance of understanding eGFR slope dynamics, asking whether acute versus chronic effects might influence interpretation of treatment benefit. In response, Perkovic explained that, unlike some other therapies, iptacopan did not appear to have an acute hemodynamic effect on eGFR, resulting in a more linear and interpretable slope over time, a point both hosts noted could simplify comparisons across agents.

Looking ahead, all three speakers emphasized the likelihood that combination approaches will be necessary, particularly for patients with high baseline proteinuria. As Perkovic pointed out during the exchange, achieving guideline-recommended targets may require multiple therapies with complementary mechanisms. Wadhwani further stressed the importance of earlier diagnosis and intervention, while Perkovic suggested that evolving data may prompt clinicians to reconsider biopsy thresholds and treatment timing.

Editors’ Note: Relevant disclosures for 

 include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Relevant disclosures for

include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. Relevant disclosures for

include Boehringer Ingelheim,AbbVie, Inc., Bristol-Myers Squibb, servier, Astellas Pharma US, Merck, Janssen Pharmaceuticals, GSK, and others.

Podcasts

Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hiddo Heerspink, PharmD, PhD, is a professor of Clinical Trials and Personalized Medicine, clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen.

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

As the treatment landscape for IgA nephropathy grows increasingly complex, new data presented at the World Congress of Nephrology 2026 in Yokohama, Japan, are beginning to clarify how emerging therapies may work together. 

, hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, sat down with Hiddo Heerspink, PhD, PharmD, to discuss the phase 2 ASSIST trial, which evaluated the efficacy and safety of atrasentan in combination with SGLT2 inhibitors.

Throughout the discussion, Heerspink emphasized that the trial was intentionally designed to address a rapidly evolving standard of care. As he explained, growing evidence supporting SGLT2 inhibitors in chronic kidney disease, specifically in IgA nephropathy, prompted the need to understand whether additional therapies like atrasentan could provide incremental benefit when layered on top. Neuen and Wadhwani both highlighted this rationale, framing the study as a forward-looking effort to anticipate real-world combination therapy.

To efficiently generate these data, Heerspink noted that the investigators used a randomized, placebo-controlled crossover design, allowing each patient to serve as their own control. As Neuen pointed out during the conversation, this approach improves statistical efficiency and reduces the required sample size. The study enrolled 51 patients, each receiving atrasentan and placebo sequentially on top of background SGLT2 inhibition, with both short-term (12-week) and longer-term (24-week) treatment periods incorporated into the design.

Wadhwani underscored another key distinction raised by Heerspink: the inclusion of patients with lower levels of proteinuria, starting at 0.5 g/day. According to Heerspink, this decision, made before the latest guideline updates, allowed the trial to explore efficacy in a broader, earlier-stage population than many prior phase 3 studies. Both hosts noted how this aligns with a growing emphasis on earlier diagnosis and intervention in IgA nephropathy.

In presenting the results, Heerspink stated that atrasentan reduced proteinuria by approximately 25% compared with placebo when added to SGLT2 inhibitors, with effects apparent by 12 weeks and sustained through 24 weeks. He further emphasized that the drug did not produce an acute decline in eGFR, challenging longstanding assumptions about endothelin receptor antagonists, and that its effects on blood pressure were modest.

Safety was a central focus of the discussion. Heerspink highlighted concerns around fluid retention with this class of agents but noted that, in ASSIST, these risks were minimal when atrasentan was combined with SGLT2 inhibitors. Both Neuen and Wadhwani pointed to the reassuring safety signals, including stable body weight and no clinically meaningful changes in biomarkers, reinforcing Heerspink’s conclusion that the combination appears both safe and well tolerated.

Looking beyond the trial, the conversation turned to broader implications for clinical practice and research design. Wadhwani raised the potential for crossover studies to help individualize therapy, prompting Heerspink to suggest that such designs could offer insight into patient-specific responses. However, he cautioned that variability in proteinuria measurements must be carefully considered when interpreting individual-level changes.

Heerspink additionally challenged the conventional sequencing of therapies. As he explained during the episode, the order in which drugs are developed should not dictate how they are used in practice. Instead, he advocated for a more pathophysiology-driven approach, tailoring treatment selection and sequencing to disease mechanisms and stage rather than defaulting to historical standards of care.

 include AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chinook Therapeutics Inc., Gilead Sciences, Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Travere Therapeutics, and others. Relevant disclosures for 

 include AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen, and others. Relevant disclosures for 

include the National Institute of Diabetes and Digestive and Kidney Diseases, GSK, Calliditas and Travere Therapeutics.

Hiddo Heerspink, MD, PhD, highlights ASSIST trial data showing atrasentan reduced proteinuria by 25% on top of SGLT2 inhibitors in IgA nephropathy.

Swapnil Hiremath, MD, MPH, is a Staff Nephrologist at the Ottawa Hospital, a Professor in the Faculty of Medicine, cross appointed to the School of Epidemiology and Public Heath at the University of Ottawa, and also an Associate Scientist in the Clinical Epidemiology Programme at the Ottawa Hospital Research Institute.

Bridging the Gap in Hypertension Care Delivery, With Swapnil Hiremath, MD, MPH

Hypertension remains one of the most consequential but uncontrolled drivers of global morbidity and mortality. Affecting more than 1 billion people worldwide, it is the leading modifiable risk factor for death, contributing to millions of preventable deaths each year.

Despite the availability of effective, low-cost therapies, blood pressure control rates have stagnated or even declined in many regions, highlighting a critical gap not in knowledge, but in implementation. Programs like the World Health Organization’s Global HEARTS Initiative aim to close this gap by focusing on scalable, system-level solutions.

 at at the World Congress of Nephrology (WCN) Conference in Yokohama, Japan, Swapnil Hiremath, MD, MPH, a nephrologist at the Ottawa Hospital and professor at the University of Ottawa, emphasized that the challenge is not a lack of effective treatments, but rather the failure to consistently apply simple, evidence-based strategies in real-world settings.

“Even if you look at high income countries, BP control is hard, and sometimes we don't do the simple things well,” Hiremath said.

He notes that even modest reductions in blood pressure can yield substantial benefits, including meaningful decreases in cardiovascular events, stroke, heart failure, and overall mortality. However, these gains are often unrealized due to fragmented care systems, limited access to medications, and clinical inertia.

The HEARTS framework, he explains, is designed to address these barriers through a comprehensive yet practical approach. Built around key pillars including healthy lifestyle counseling, standardized treatment protocols, access to essential medications, risk-based management, team-based care, and systems for monitoring, HEARTS prioritizes feasibility and adaptability across diverse healthcare settings.

Hiremath notes that a central component of this approach is the emphasis on affordability and accessibility. He highlights the strategic use of widely available, low-cost medications such as calcium channel blockers, angiotensin receptor blockers, and thiazide diuretics, therapies selected not only for efficacy, but also for their safety profiles and minimal need for laboratory monitoring, which are critical considerations in low-resource environments where access to follow-up care may be limited.

He also underscores the importance of team-based care models, which enable non-physician providers to follow structured treatment algorithms and escalate therapy efficiently. This approach helps overcome workforce limitations and reduces delays in treatment intensification, a common contributor to poor blood pressure control.

While the program has made meaningful progress, reaching tens of millions of individuals across dozens of countries, Hiremath notes that this represents only a fraction of the global burden. Expanding implementation will require sustained political commitment, local adaptation, and continued focus on health system strengthening.

“The solutions are there. We don't have to invent a vaccine, we don't need new technology, we don't need any fancy drugs,” he said. “We have the tools, it's just about implementation.”

Editors’ Note: Hiremath reports no relevant disclosures.

Farrar J, Frieden T. WHO global report on hypertension 2025. The Lancet. doi:

World Health Organization. Global Hearts Initiative. Accessed March 29, 2026. 

https://www.who.int/initiatives/global-hearts-initiative

Videos

Hypertension drives millions of preventable deaths, yet control lags globally. The HEARTS framework offers practical, scalable solutions to close this gap.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Can CAR-T Cell Therapy Transform Lupus Nephritis Care? With Brad Rovin, MD

The treatment of lupus nephritis has long been challenged by profound disease heterogeneity and incomplete responses to standard immunosuppressive therapies. Despite recent advances and newly approved agents, many patients still fail to achieve complete remission. Against this backdrop, the emergence of CAR-T cell therapy represents a potentially transformative step, rooted in the field’s broader shift toward precision medicine and deeper immune modulation.

 at the World Congress of Nephrology (WCN) Conference in Yokohama, Japan, Brad Rovin, MD, explains how the field has historically relied on broadly acting immunosuppressive approaches, such as high-dose cyclophosphamide or mycophenolate, which “treat everything” but fail to account for the biological variability across patients. He says that this one-size-fits-all strategy is increasingly being replaced by efforts to tailor therapy more precisely, particularly as it has become clear that more than half of patients do not achieve complete clinical remission with existing options.

“I think with the idea of using something like a CAR-T cell, we borrow a lot of things from oncology, there's no question about it,” he said. “The idea was, could we affect the immune system in a way that renders it less likely to attack in an autoimmune way for some prolonged period of time? I'm hesitant to use the word cure, because I don't know that we've established cure yet. I think the CAR-T data show that we can, in some patients, achieve a prolonged drug free response. Whether that is a cure in some people, we'll see.”

A key differentiator, Rovin explains, lies in the depth and breadth of B-cell targeting. Unlike conventional anti-CD20 therapies like obinutuzumab (Gazyva), which target a narrower subset of B cells, CAR-T therapies directed at CD19 affect a broader range of the B-cell lineage, including antibody-producing populations. He highlights that CAR-T therapy also appears to induce more complete depletion within lymphoid tissues, including germinal centers, which may be critical for sustained disease control and may go beyond what is achieved with current therapies.

He describes the most striking findings to date as reports of sustained clinical remission lasting up to 4 years without ongoing immunosuppression. However, he emphasizes that these results are not universal, and the therapy carries significant risks, including profound immunosuppression and potential toxicities.

Looking ahead, Rovin stresses the importance of careful patient selection, transparent communication, and continued clinical investigation. While CAR-T therapy may represent a paradigm shift in lupus care, defining its long-term role and balancing its promise with its risks will be essential as the field moves forward.

“I think now it's up to us to continue the investigations, which are ongoing, and now trials are enrolling pretty well and and try to sort these issues out, but like any new therapy, there's going to be bumps, and I think that this is important to think about when we talk to our patients and families about this,” he said.

Editors’ Note: Relevant disclosures for Rovin include Biogen, GSK, Genentech/Roche, BMS, Travere, Alexion, Novartis, AstraZeneca, Otsuka, Calliditis, and others.

Brooks A. FDA Approves Obinutuzumab (Gazyva) for Lupus Nephritis. RheumatologyLive. October 20, 2025. Accessed March 29, 2026. 

https://www.rheum-live.com/view/fda-approves-obinutuzumab-gazyva-for-lupus-nephritis

Musa R, Rout P, Qurie A. Lupus Nephritis. StatPearls. January 16, 2025. Accessed March 29, 2026. 

https://www.ncbi.nlm.nih.gov/books/NBK499817/

CAR-T therapy shows potential for deep, durable remission in lupus nephritis, but questions remain on safety, durability, and patient selection.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Nicholas Marston, MD
Credit: American College of Cardiology

An analysis of the VESALIUS-CV trial is extending the evidence base for 

 beyond established secondary prevention populations.

A prespecified subgroup analysis of the VESALIUS-CV trial, results suggest the PCSK9 inhibitor evolocumab significantly reduced the risk of a first major cardiovascular event in high-risk primary prevention patients with diabetes and no known significant atherosclerosis.

“I think this study changes the paradigm,” said Nicholas Marston, MD, MPH, a cardiologist and assistant professor of medicine at Brigham and Women’s Hospital and Harvard Medical School, who presented the data at the 

American College of Cardiology's Annual Scientific Session (ACC.26)

N=3655; all had diabetes, no known significant atherosclerosis

Median achieved LDL-C at 48 weeks: 52 mg/dL (evolocumab) vs 111 mg/dL (placebo)

VESALIUS-CV Subgroup Design and Population

VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries, enrolling 12,257 patients without prior myocardial infarction or stroke who had qualifying atherosclerosis or high-risk diabetes and an LDL-C level of 90 mg/dL or greater.

This prespecified subgroup analysis examined the 3655 patients without known significant atherosclerosis, defined as the absence of prior arterial revascularization, arterial stenosis of 50% or greater, or a coronary artery calcium score of 100 Agatston units or greater. All patients in this subgroup had diabetes and the median follow-up was 4.8 years.

Patients were randomized 1:1 to subcutaneous evolocumab 140 mg every 2 weeks or matching placebo added to optimally tolerated statin therapy. The median age was 65 years, 57% were female, 89% were receiving lipid-lowering therapy at baseline, and 64% were on high-intensity statin therapy. Median baseline LDL-C was 132 mg/dL.

The dual primary endpoints were 3-point MACE, which was defined as coronary heart disease death, myocardial infarction, or ischemic stroke, and 4-point MACE, which also included ischemia-driven arterial revascularization.

31% Reduction in MACE Across Both Primary Endpoints

At the 5-year Kaplan-Meier estimate, evolocumab reduced the 3-point MACE rate from 7.1% to 5.0% (hazard ratio [HR], 0.69; 95% CI, 0.52-0.91; 

= .009), representing a between-group difference of 2.1%. The 4-point MACE rate was reduced from 10.5% to 7.6% (HR, 0.69; 95% CI, 0.55-0.86; 

= .001), a between-group difference of 2.9%.

Evolocumab also reduced the risk of cardiovascular death (HR, 0.68; 95% CI, 0.46-0.99) and all-cause mortality (HR, 0.76; 95% CI, 0.61-0.95), though the investigators noted that due to the prespecified hierarchical testing order, mortality reductions should be considered exploratory. Among the lipid substudy participants, median LDL-C at 48 weeks was 52 mg/dL in the evolocumab group versus 111 mg/dL in the placebo group.

An additional analysis demonstrated the treatment benefit became more apparent after year 1, with 41% and 39% reductions in 3-point and 4-point MACE risk in subsequent years, consistent with an expected lag in clinical benefit in patients without pre-existing plaque.

The investigators noted current US guidelines assign only a class 2b recommendation for adding a nonstatin agent in high-risk primary prevention patients with diabetes whose LDL-C remains above 70 mg/dL, resulting in infrequent intensification of therapy in this population.

“In current practice, PCSK9 inhibitors are largely reserved for patients who have had a prior heart attack or stroke,” Marston added. “But here we see a benefit of using evolocumab not only to treat patients without a history of heart attack or stroke, but without known significant atherosclerosis. It’s a message to physicians and patients that we don’t have to wait until someone has atherosclerosis to treat them intensively. We can—and should—be much more proactive.”

Investigators called attention to several limitations warranting consideration. These included the analysis being a prespecified subgroup, imaging to detect atherosclerosis was not performed in all patients, and the population was predominantly White and entirely composed of high-risk diabetic patients.

Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. Published online March 28, 2026. doi:

American College of Cardiology. Evolocumab Cuts Cardiac Risk in Patients Without Known Atherosclerosis and With Diabetes - American College of Cardiology. American College of Cardiology. Published March 28, 2026. Accessed March 28, 2026. 

https://www.acc.org/About-ACC/Press-Releases/2026/03/28/15/33/Evolocumab-Cuts-Cardiac-Risk-in-Patients-Without-Known-Atherosclerosis-and-With-Diabetes 

Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. 

. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006

Articles

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Type 2 Diabetes

VESALIUS-CV: Evolocumab Cuts First MACE Risk in Diabetes Without Atherosclerosis

New data from the KARDINAL trial at ACC.26 provides insight, but raises questions regarding tonlamarsen and hypertension. 

Monthly Tonlamarsen Reduces Angiotensinogen, But No Significant Difference in Blood Pressure

Amy Sarma, MD, is the Cathy E. Minehan Endowed Chair in Cardiology and co-director of the Corrigan Women’s Heart Health Program and Cardiovascular Disease and Pregnancy Programs at the Massachusetts General Hospital.

Sarma discusses the ongoing movement to highlight the different cardiovascular risks facing women, particularly during the most turbulent periods of life.

Strategic Alliance Partnership

Combatting Cardiovascular Risk in Postpartum and Menopausal Women, With Amy Sarma, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Sustained Itch Reduction Observed at 1 Year of Icotrokinra in Psoriasis, With Linda Stein Gold, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

KEEPsAKE-1: Risankizumab Maintains Radiographic Nonprogression Through 5 Years in Psoriatic Arthritis

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

Alopecia

First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Late-Breaking Data Highlight Nemolizumab Efficacy in Children with Atopic Dermatitis

HI-PEITHO concluded use of ultrasound-facilitated catheter-directed fibrinolysis improves pulmonary embolism outcomes. 

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Ultrasound-Facilitated Catheter-Directed Fibrinolysis Reduces Early Decompensation in Pulmonary Embolism

Arrhythmia

CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

ICONIC-LEAD: 1 Year Icotrokinra Data Confirm Durable Psoriasis Clearance, PRO Improvements in Adults, Adolescents, With Jennifer Soung, MD

Petter Bjornstad, MD, is executive director of the UW Medicine Diabetes Institute, professor of pediatrics and medicine, and the Raisbeck Endowed Chair of Diabetes Research at the University of Washington.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

Latest News

Kidney Compass: New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

Bridging the Gap in Hypertension Care Delivery, With Swapnil Hiremath, MD, MPH

Can CAR-T Cell Therapy Transform Lupus Nephritis Care? With Brad Rovin, MD

VESALIUS-CV: Evolocumab Cuts First MACE Risk in Diabetes Without Atherosclerosis